Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IMNN
IMNN logo

IMNN News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

IMNN News

IMUNON Announces Transition in Financial Leadership

1d agoseekingalpha

Biotech Sector Update: FDA and EU Approvals

6d agoNASDAQ.COM

Virtual Investor Conferences Forum Highlights

6d agoGlobenewswire

Agenda Announced for Life Sciences Virtual Investor Forum

Jun 23 2026Globenewswire

IMUNON CEO to Present at Life Sciences Investor Forum

Jun 22 2026Newsfilter

IMUNON Secures $10 Million Financing for Clinical Trials

Jun 05 2026NASDAQ.COM

IMUNON Secures $10 Million Financing Agreement

Jun 04 2026seekingalpha

Imunon IMNN Q4 2025 Earnings Transcript

Jun 01 2026NASDAQ.COM

IMNN Events

06/30 18:30
Imunon Appoints Josh Blacher as New Interim CFO
In a regulatory filing, the company stated, "On June 29, 2026, Jeffrey Church informed Imunon of his intent to retire from the position of interim Chief Financial Officer, a position he has held since January of 2026, effective July 1, 2026. To help ensure a smooth transition of his responsibilities to his successor, Church and the company agreed that he will continue in a consulting role with the company. As a result of Mr. Church's retirement, effective July 1, 2026, the company appointed Josh Blacher to serve as the company's new interim Chief Financial Officer under a master services agreement, dated June 24, 2026, between the company and Danforth Health, Inc., a financial advisory services firm. Mr. Blacher will serve as the company's principal financial officer and principal accounting officer."
06/23 08:30
Imunon OVATION 3 Clinical Trial Continues
Imunon announced that the independent Data Monitoring Committee, or IDMC, has recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with standard of care neoadjuvant and adjuvant chemotherapy in women with newly diagnosed advanced ovarian cancer. "We are very pleased that the iDMC has recommended continuation of the landmark OVATION 3 clinical trial without modification, representing another important validation of the remarkable efficacy and safety data previously reported and further indicating the potential for IMNN-001 to represent a historic advance in the treatment of ovarian cancer," said Stacy Lindborg, president and chief executive officer of Imunon. "We remain ahead of our anticipated schedule in patient enrollment and this recommendation by the iDMC brings new levels of momentum to our efforts to advance this trial as rapidly as possible."
05/12 08:10
IMUNON's OVATION 3 Trial Enrollment Exceeds Expectations
"Enrollment in our pivotal Phase 3 OVATION 3 trial continues ahead of plan, reflecting patient interest and strong conviction among principal investigators and the broader medical community in IMNN-001's therapeutic potential," said Stacy Lindborg, President and Chief Executive Officer of IMUNON. "Coupled with the unprecedented overall survival benefit observed in our Phase 2 study and an aligned path to BLA filing, IMNN-001 is well positioned to potentially transform the standard of care in advanced ovarian cancer."

IMNN Monitor News

Imunon Inc stock rises after crossing above 5-day SMA

Jun 17 2026

Imunon Inc stock declines amid market gains

Mar 25 2026

IMNN Earnings Analysis

No Data

No Data

People Also Watch